Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Phase 2 Study Comparing Chemotherapy in Combination With OGX-427 or Placebo in Patients With Bladder Cancer
NCT01454089 · View on ClinicalTrials.gov ↗
Study Summary
The primary objective of this study is to ascertain whether there is evidence of longer survival relative to the control arm for three comparisons: 600 mg OGX-427 Arm to control Arm; 1000 mg OGX-427 Arm to control Arm; and pooled 600 mg and 1000 mg OGX-427 Arms to control Arm.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Cisplatin
- DRUG Gemcitabine
- DRUG OGX-427 600 mg
- DRUG OGX-427 1000 mg
Study Locations (20)
California
- City of Hope National Medical Center — Duarte
- Cedars-Sinai Medical Center — Los Angeles
- University of California Los Angeles — Los Angeles
- USC Norris Comprehensive Cancer Center — Los Angeles
- Radiological Associates of Sacramento — Sacramento
New York
- Monter Cancer Center — Lake Success
- Columbia University Medical Center — New York
- Montefiore Medical Center, Albert Einstein College of Medicine — The Bronx
Ontario
- Juravinski Cancer Centre — Hamilton
- R. S. McLaughlin Durham Regional Cancer Center at Lakeridge Health — Oshawa
- Princess Margaret Hospital — Toronto
Alberta
- Tom Baker Cancer Center — Calgary
- Cross Cancer Center — Edmonton
Connecticut
- Yale University — New Haven
Michigan
- Karmanos Cancer Institute — Detroit
Missouri
- Siteman Cancer Center, Washington University School of Medicine — St Louis
Nebraska
- Urology Cancer Center and GU Research Network — Omaha
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 183 participants |
| Start Date | 2011-10 |
| Est. Completion | 2014-11 |
| Phase | Phase 2 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01454089
The ClinicalTrials.gov registry entry for NCT01454089 describes a study currently listed as completed. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 183 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Achieve Life Sciences, which has 2 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 3 conditions, with Urologic Neoplasms appearing as the primary indexed condition, and to 5 interventions — of which Placebo is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT01454089 reports 20 study locations spanning 11 distinct geographic areas — top geographies include California, New York, Ontario. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT01454089 about?
NCT01454089 is a clinical study titled "A Phase 2 Study Comparing Chemotherapy in Combination With OGX-427 or Placebo in Patients With Bladder Cancer". The primary objective of this study is to ascertain whether there is evidence of longer survival relative to the control arm for three comparisons: 600 mg OGX-427 Arm to control Arm; 1000 mg OGX-427 Arm to control Arm; and pooled 600 mg and 1000 mg OGX-427 Arms to control Arm.
What is the current status of trial NCT01454089?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 183 participants. The study started on 2011-10. Estimated completion is 2014-11.
What conditions does trial NCT01454089 study?
This clinical trial studies the following conditions: Urologic Neoplasms, Metastatic Bladder Cancer, Urinary Tract Neoplasms. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT01454089?
The interventions under investigation include: Placebo (DRUG), Cisplatin (DRUG), Gemcitabine (DRUG), OGX-427 600 mg (DRUG), OGX-427 1000 mg (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT01454089?
This trial is sponsored by Achieve Life Sciences, which has 2 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT01454089 being conducted?
This trial has 20 study locations across California, Connecticut, Michigan, Missouri, Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.